First-in-human imaging of EphA2 using 68Ga-DOTA-EphA2 PET/CT

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop and test a novel 68Ga-labeled tracer that targets EphA2, a receptor linked to tumor progression. Participants will undergo PET/CT imaging after administration of the tracer to visualize EphA2-positive malignancies. The study will assess imaging feasibility, safety, and the tracer’s ability to provide specific information about EphA2 expression in vivo. Eligible adults with solid tumors and measurable disease will be evaluated under standard imaging workflows, with careful monitoring for adverse effects and imaging quality. No therapeutic intervention is described in this protocol; the focus is on imaging biomarker discovery and characterization.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18-80 years
* Patients with suspected or histologically confirmed malignant tumors At least one measurable lesion identified by conventional imaging (CT, MRI, or ultrasound)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Ability to understand the study procedures and provide written informed consent
* Adequate organ function allowing PET/CT examination

Exclusion Criteria:

* Pregnant or breastfeeding women
* Severe hepatic, renal, cardiovascular, or pulmonary dysfunction considered --unsuitable for PET/CT imaging
* Known allergy or hypersensitivity to study-related compounds
* Patients unable to tolerate PET/CT examination or remain still during image acquisition
* Participation in other investigational drug or radionuclide studies within 4 weeks prior to enrollment
* Any medical or psychiatric condition judged by the investigators to interfere with study participation or interpretation of imaging results

Where it's running

• PET
  Shenyang, Liaoning, China Recruiting

Study contacts

• Study coordinator: Shu Wang, PhD
• Email: shuwang201508@163.com
• Phone: 15040289429

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding targeted GRID-style radiation to standard palliative therapy for unresectable solid tumors

  This study tests whether adding spatially fractionated radiation therapy to standard palliative radiation helps relieve symptoms in patients with unresectable solid tumors.

  Recruiting at 2 sites Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT07856394

• Irradiated tumor-and-stroma vaccine for advanced solid tumors

  This Phase 1 test will try an irradiated vaccine made from tumor cells and nearby stromal cells, with or without GM-CSF, to see if it is safe and can stimulate the immune system in people with advanced solid tumors.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan and 1 other locations · NCT07567222

• Al18F‑NOTA‑FAPI PET imaging for cancer, cardiovascular, and autoimmune conditions

  This trial will test a new PET tracer called Al18F‑NOTA‑FAPI to image fibroblast activity in adults with cancer, heart disease, or autoimmune conditions and in healthy volunteers to see how safe and useful it is for guiding care.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing · NCT07400224

• Psychological distress and its effects on treatment adherence, outcomes, and quality of life in people with cancer

  This study will try to see if anxiety and depression change how adults with cancer stick to treatment, their health outcomes, and their quality of life over three years.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07193329

• Pre-treatment rehabilitation program for cancer patients

  This study is testing whether a special exercise and support program before cancer treatment can help high-risk patients feel better and have improved results during their care.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06674889

• Evaluating central oncology navigation and a new oncology research navigator for cancer care

  This study is testing if a new support system for cancer patients can help improve their care experience, focusing on those newly diagnosed with certain types of cancer.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06618274

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.